{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:13:25Z","timestamp":1787807605892,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.msard.2024.105524","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T16:52:19Z","timestamp":1709311939000},"page":"105524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0892-8669","authenticated-orcid":false,"given":"Seraj","family":"Makkawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7860-4711","authenticated-orcid":false,"given":"Hassan K.","family":"Salamatullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alkhiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania E.","family":"Faidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Afif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad I.","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abulaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Al Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2024.105524_bib0001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1212\/WNL.0000000000012175","article-title":"Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder","volume":"97","author":"Akaishi","year":"2021","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.msard.2024.105524_bib0002","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: a Review in Neuromyelitis Optica Spectrum Disorder [published correction appears in Drugs. 2020 Apr 21;:] [published correction appears in Drugs. 2020 Apr 22;:]","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.msard.2024.105524_bib0003","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105524_bib0004","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4","first-page":"2023","article-title":"Chapter 8: assessing risk of bias in a randomized trial","author":"Higgins","year":"2023"},{"issue":"12","key":"10.1016\/j.msard.2024.105524_bib0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2024.105524_bib0006","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2024.105524_bib0007","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","article-title":"The Use of External Controls in FDA Regulatory Decision Making","volume":"55","author":"Jahanshahi","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"6","key":"10.1016\/j.msard.2024.105524_bib0008","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.msard.2024.105524_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231181177","article-title":"Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan","volume":"16","author":"Nakashima","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2024.105524_bib0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.105524_bib0011","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.msard.2024.105524_bib0012","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105524_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102641","article-title":"Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial","volume":"47","author":"Palace","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2024.105524_bib0014","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2024.105524_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S1092852920001625","article-title":"Response to: eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder","volume":"26","author":"Pittock","year":"2021","journal-title":"CNS. Spectr."},{"issue":"3","key":"10.1016\/j.msard.2024.105524_bib0016","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2024.105524_bib0017","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"issue":"15","key":"10.1016\/j.msard.2024.105524_bib0018","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.msard.2024.105524_bib0019","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.msard.2024.105524_bib0020","article-title":"Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment [published online ahead of print, 2023 Aug 25]","volume":"79","author":"Sen","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105524_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.696387","article-title":"Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder","volume":"12","author":"Singh","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105524_bib0022","unstructured":"VassarStats: Statistical Computation. Accessed October 12th, 2023. http:\/\/vassarstats.net\/."},{"issue":"5","key":"10.1016\/j.msard.2024.105524_bib0023","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM. Evid."},{"issue":"6","key":"10.1016\/j.msard.2024.105524_bib0024","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:40:13Z","timestamp":1738064413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"alternative-id":["S2211034824001032"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105524","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105524"}}